AUTL
Autolus Therapeutics·NASDAQ
--
--(--)
--
--(--)
7.75 / 10
Outperform
Fund flow is robust (7.8/10), with large and extra‑large investors net inflowing, while small/medium show outflows. Analyst sentiment is overwhelmingly bullish—100% Strong Buy from Needham—yet the analyst’s past win rate is only 33% and the stock has dropped 15.9%. Caution advised.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-27
InstitutionNeedham
Times predicted9
Historical Win Rate33.3%
What is the analyst consensus for AUTL?
- AUTL holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 7.75/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
